Compare Global X FTSE Southeast Asia ETF (ASEA) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs Citius Pharmaceuticals Inc — how do they compare? Global X FTSE Southeast Asia ETF trades at $20.65, while Citius Pharmaceuticals Inc trades at $0.58 (market cap $16.00M). The key difference: Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ASEA | CTXR | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $20.65 | $1.82 |
52-Week Low | $16.31 | $0.53 |
Market Cap | — | $16.00M |
Enterprise Value | — | $12.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASEA stock trades at $20.65, up 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong momentum with an ADX of 49.11 indicating a trending market. Recent corporate actions include a declared dividend of $0.41 per share scheduled for July 2026. Key support and resistance levels are clustered around $20-$21, suggesting a critical price zone for near-term direction.
The outlook remains cautiously optimistic given technical strength, but fundamental data is currently unavailable for a complete assessment. Risks include potential volatility near key technical levels and reliance on future financial performance disclosures. Investors should await upcoming earnings reports for clarity on valuation and profitability metrics.
CTXR trades at $0.5827, up 3.81% today, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported a net loss of $37.43M in 2025 with a -823.34% net margin, though revenue reached $5.6M in H1 2026 from LYMPHIR commercialization. Recent news highlights positive Phase 1 data for LYMPHIR presented at ASCO 2026.
Outlook remains speculative with high cash burn offset by financing; analyst consensus is 83% buy but financial sustainability depends on successful drug adoption. Key risks include clinical trial outcomes, dilution from recent $5M offering, and achieving profitability amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
